Champions Oncology Stock Price, News & Analysis (NASDAQ:CSBR)

$3.64 -0.03 (-0.82 %)
(As of 11/17/2017 04:00 PM ET)
Previous Close$3.67
Today's Range$3.56 - $3.73
52-Week Range$1.75 - $4.79
Volume15,762 shs
Average Volume52,400 shs
Market Capitalization$38.02 million
P/E RatioN/A
Dividend YieldN/A

About Champions Oncology (NASDAQ:CSBR)

Champions Oncology logoChampions Oncology, Inc. is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS segment provides physicians and patients information to help guide the development of personalized treatment plans. The TOS segment provides services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. Its TumorGraft Technology Platform consists of processes, physical tumors and information that it uses to personalize the development and use of oncology drugs. Each tumor from patients that it has preserved for implantation in mice, along with the patient data and molecular information associated with the tumors, are known as TumorGrafts or Patient Derived XenoGrafts of PDX Models. The collection of TumorGrafts is referred to as the Company's TumorBank.

Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:CSBR
  • CUSIP: N/A
  • Web:
  • Current Ratio: 0.57%
  • Quick Ratio: 0.57%
Sales & Book Value:
  • Annual Sales: $15.41 million
  • Price / Sales: 2.60
  • Book Value: $0.04 per share
  • Price / Book: 91.00
  • Trailing EPS: ($0.46)
  • Net Income: ($6,880,000.00)
  • Net Margins: -29.87%
  • Return on Equity: -338.01%
  • Return on Assets: -66.70%
  • Employees: 79
  • Outstanding Shares: 10,990,000
Frequently Asked Questions for Champions Oncology (NASDAQ:CSBR)

What is Champions Oncology's stock symbol?

Champions Oncology trades on the NASDAQ under the ticker symbol "CSBR."

How were Champions Oncology's earnings last quarter?

Champions Oncology, Inc. (NASDAQ:CSBR) issued its earnings results on Thursday, September, 14th. The biotechnology company reported ($0.06) EPS for the quarter. The biotechnology company had revenue of $5.03 million for the quarter. Champions Oncology had a negative return on equity of 338.01% and a negative net margin of 29.87%. View Champions Oncology's Earnings History.

When will Champions Oncology make its next earnings announcement?

Champions Oncology is scheduled to release their next quarterly earnings announcement on Monday, November, 27th 2017. View Earnings Estimates for Champions Oncology.

Who are some of Champions Oncology's key competitors?

Who are Champions Oncology's key executives?

Champions Oncology's management team includes the folowing people:

  • Joel Ackerman, Chairman of the Board (Age 51)
  • Ronnie Morris M.D., President, Chief Executive Officer, Director (Age 49)
  • David Miller CPA, Vice President - Finance (Age 46)
  • Philip Breitfeld, Chief Strategic and Innovation Officer, Director (Age 63)
  • David Sidransky M.D., Lead Independent Director (Age 56)
  • Daniel N. Mendelson, Independent Director (Age 52)
  • Abba David Poliakoff, Independent Director (Age 64)
  • Scott R. Tobin, Independent Director (Age 45)

Who owns Champions Oncology stock?

Champions Oncology's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (3.52%). Company insiders that own Champions Oncology stock include Joel Ackerman and Ronnie Morris. View Institutional Ownership Trends for Champions Oncology.

Who bought Champions Oncology stock? Who is buying Champions Oncology stock?

Champions Oncology's stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC. Company insiders that have bought Champions Oncology stock in the last two years include Joel Ackerman and Ronnie Morris. View Insider Buying and Selling for Champions Oncology.

How do I buy Champions Oncology stock?

Shares of Champions Oncology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Champions Oncology's stock price today?

One share of Champions Oncology stock can currently be purchased for approximately $3.64.

How big of a company is Champions Oncology?

Champions Oncology has a market capitalization of $38.02 million and generates $15.41 million in revenue each year. The biotechnology company earns ($6,880,000.00) in net income (profit) each year or ($0.46) on an earnings per share basis. Champions Oncology employs 79 workers across the globe.

How can I contact Champions Oncology?

Champions Oncology's mailing address is One University Plaza Suite 307, Hackensack NJ, 07601. The biotechnology company can be reached via phone at 201-808-8400 or via email at [email protected]

MarketBeat Community Rating for Champions Oncology (NASDAQ CSBR)
Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  17 (Vote Outperform)
Underperform Votes:  19 (Vote Underperform)
Total Votes:  36
MarketBeat's community ratings are surveys of what our community members think about Champions Oncology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Ratings for Champions Oncology (NASDAQ:CSBR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Analysts' Consensus Price Target: N/A
Consensus Price Target History for Champions Oncology (NASDAQ:CSBR)
Price Target History for Champions Oncology (NASDAQ:CSBR)
Analysts' Ratings History for Champions Oncology (NASDAQ:CSBR)
No equities research coverage for this company has been tracked by


Earnings History for Champions Oncology (NASDAQ:CSBR)
Earnings by Quarter for Champions Oncology (NASDAQ:CSBR)
Earnings History by Quarter for Champions Oncology (NASDAQ CSBR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/27/2017N/AView Earnings Details
9/14/2017Q1 2018($0.06)$5.03 millionViewN/AView Earnings Details
7/27/2017Q4 2017($0.22)$3.72 millionViewN/AView Earnings Details
3/16/2017Q3 2017($0.13)$3.57 millionViewN/AView Earnings Details
11/29/2016Q2 2017($0.05)$4.46 millionViewN/AView Earnings Details
3/15/2016Q316($0.21)$1.80 million$2.60 millionViewListenView Earnings Details
12/12/2013Q1 14($0.03)ViewN/AView Earnings Details
9/13/2013Q1($0.02)ViewN/AView Earnings Details
3/14/2013Q3 13($0.01)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Champions Oncology (NASDAQ:CSBR)

No earnings estimates for this company have been tracked by


Dividend History for Champions Oncology (NASDAQ:CSBR)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Champions Oncology (NASDAQ CSBR)
Insider Ownership Percentage: 44.30%
Institutional Ownership Percentage: 37.93%
Insider Trades by Quarter for Champions Oncology (NASDAQ:CSBR)
Insider Trades by Quarter for Champions Oncology (NASDAQ:CSBR)
Insider Trades by Quarter for Champions Oncology (NASDAQ CSBR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/21/2016Ronnie MorrisPresidentBuy30,000$1.66$49,800.00View SEC Filing  
10/19/2016Ronnie MorrisPresidentBuy10,000$1.70$17,000.00View SEC Filing  
10/18/2016Joel AckermanCEOBuy2,000$1.70$3,400.00View SEC Filing  
10/14/2016Joel AckermanCEOBuy7,300$1.67$12,191.00View SEC Filing  
10/14/2016Ronnie MorrisPresidentBuy10,305$1.66$17,106.30View SEC Filing  
10/13/2016Ronnie MorrisPresidentBuy29,695$1.67$49,590.65View SEC Filing  
10/10/2016Ronnie MorrisPresidentBuy9,537$1.66$15,831.42View SEC Filing  
10/7/2016Joel AckermanCEOBuy8,202$1.63$13,369.26View SEC Filing  
9/23/2016Joel AckermanCEOBuy33$1.65$54.45View SEC Filing  
9/21/2016Joel AckermanCEOBuy5,000$1.66$8,300.00View SEC Filing  
9/20/2016Ronnie MorrisPresidentBuy3,000$1.58$4,740.00View SEC Filing  
3/11/2015Michael Maurice BrownMajor ShareholderBuy6,250,000$0.40$2,500,000.00View SEC Filing  
3/20/2014Daniel Newman MendelsonDirectorBuy100,000$1.08$108,000.00View SEC Filing  
3/19/2014Ronnie MorrisPresidentBuy100,000$1.07$107,000.00View SEC Filing  
1/28/2013Michael Maurice BrownMajor ShareholderBuy7,000,000$0.50$3,500,000.00View SEC Filing  
1/28/2013Ronnie MorrisPresidentBuy500,000$0.50$250,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Champions Oncology (NASDAQ:CSBR)
Latest Headlines for Champions Oncology (NASDAQ CSBR)
No headlines for this company have been tracked by

Social Media



Champions Oncology (NASDAQ CSBR) Chart for Friday, November, 17, 2017
Loading chart…

This page was last updated on 11/17/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.